2015.3
- Categories:发展历程
- Author:
- Origin:
- Time of issue:2015-03-01
- Views:0
(Summary description)In March 2015, with a valuation of 250 million yuan and a financing of 150 million yuan, it became an enterprise under the top 500 Yatai Group in China. In June 2015, it initiated the phase I clinical trial of Vicagrelor. In January, the phase I clinical trial of Vicagrelor was completed.
2015.3
(Summary description)In March 2015, with a valuation of 250 million yuan and a financing of 150 million yuan, it became an enterprise under the top 500 Yatai Group in China. In June 2015, it initiated the phase I clinical trial of Vicagrelor. In January, the phase I clinical trial of Vicagrelor was completed.
- Categories:发展历程
- Author:
- Origin:
- Time of issue:2015-03-01
- Views:0
In March 2015, with a valuation of 250 million yuan and a financing of 150 million yuan, it became an enterprise under the top 500 Yatai Group in China. In June 2015, it initiated the phase I clinical trial of Vicagrelor. In January, the phase I clinical trial of Vicagrelor was completed.
Scan the QR code to read on your phone
Relevant news
Contact Us
Add:No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏ICP备2021019595号-1 Powerby:300.cn